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MATERIALS AND METHODS
Mice. Female BIO.BR (H-2k), CBA (H-2'), C57BL/6 (H-2b), (C57BL/6 X A/J) F, mice (B6AF,; H-2h X H-2") were purchased from Jackson Laboratories (Bar Harbor, ME). Donors and recipients in this study were between the ages of 8 and 12 weeks, and were housed in sterilized microisolator cages in which they received autoclaved food and autoclaved acidified water for 2 weeks after BMT.
Reagents. The following MoAbs were used for cell-surface analysis: phycoerythrin (PE)-conjugated anti-CD8 MoAb, fluorescein (F1TC)-conjugated anti-CD4 MoAb, and PE-conjugated anti-B220 (CD45R) MoAb clone RA3-6B227 (Pharmingen, San Diego, CA). The FITC-conjugated goat antimouse polyclonal Ab against surface IgG and IgM (sIg) heavy and light chains was purchased from Caltag Laboratories (South San Francisco, CA), and the FITC-conjugated rat antimouse anti-Mac-la (CD1 lWCDl8) MoAb clone MI/70'X was obtained from Boehringer-Mannheim (Indianapolis, IN). For detection of murine TNF-a, purified MP6-XT22 and biotin-conjugated rabbit antimouse TNF-a MoAbs" were used (Pharmingen). LPS (specific activity, 5 X IO4 endotoxin U/mg) and the alkaline phosphatase substrate 104 for detection in ELlSA were obtained from Sigma (St Louis, MO). Recombinant murine TNF-cu and polyclonal rabbit antimouse TNF-cu antibody for neutralization of TNF-a bioactivity were purchased from Genzyme Corp (Cambridge, MA). Reagents for detection of the NO metabolite nitrite (NO;), N-[ 1-naphthyllethylenediamine dihydrochloride, and sulfanilamide were purchased from Sigma. NMMA monoacetate salt was obtained from Calbiochem (La Jolla, CA).
BMTand GVHD induction. These protocols have been dewribed previously.','" In brief, for BMT across minor HA barriers, 1 x IO" nylon-wool-purified T cells from B10.BR mice were added to 5 X 10' bone marrow cells from the same donor strain, and this cell mixture was then injected intravenously (in 0.25 mL Leibovitz's L-15 media; GIBCO-BRL, Grand Island, NY) into sex-matched CBA recipient mice that had been given a lethal radiation dose of I. 100 cGy ("'CS source) in two doses separated by 3 hours. Transplanted BI0.BR mice were used as syngeneic controls. Experiments using a nonirradiated BMT model were performed by injecting freshly isolated splenocytes (6 X IO7) from B6 mice into nonirradiated B6AFl recipient mice. Cells from B6AFl mice were transplanted into syngeneic B6AF, mice as a negative control.
Cell culture. Cells were cultured in supplemented DMEM containing 1% normal mouse serum (Pel-Freez, Rogers, AR). Splenocytes were isolated from BMT recipient mice on day 7 or 13 after transplantation, and erythrocytes were lysed with NH4CI. Cultures were initiated in flat-bottomed 96-well plates at 4 X 10' splenocytes/ well and contained approximately 4.2 X IO' (syngeneic BMT) or 1.4 X 10' (allogeneic BMT) LPS-responsive surface Ig-positive (slg') cells per well. These splenocytes were cultured either in the absence or in the presence of the mitogen LPS ( I . O pg/mL). In some experiments, splenocytes were also cultured in the presence of a polyclonal antibody specific to murine TNF-a (1:400 or 1:40 vol/ vol) or NMMA was added at final concentrations of 20 to 40 pg/ mL. The arginine analog NMMA has been reported to be a specific NO synthase inhibit~r.~' Supernatants were collected after 4 hours of culture for determination of TNF-a and after 48 hours for NO;. Proliferation of GVHD splenocytes to LPS was measured after 72 hours by incorporation of 3H-thymidine (1 pCi) for the last 20 hours of incubation. The stimulation index (SI) of the proliferative response was calculated as follows: SI = proliferation in the presence of mitogen (cpm)/spontaneous proliferation (cpm).
An SI greater than 1 .0 indicates a proliferative response after mitogenic stimulation.
Assessment of NO in vivo. To measure the production of NO in vivo, blood samples were taken from the orbital sinuses of BMT recipients to determine serum levels of NO:. Analysis was performed on days 0, 6 and 13 post-BMT.
Cell-surface phenorype analysis. To analyze B-and T-cell-surface phenotypes, splenocytes from recipient mice (day I3 post-BMT) were resuspended in PBS for flow cytometric analysis. Cells (0.5 X 10' ) were incubated for 20 minutes at 4°C with MoAb 2.462 to block nonspecific staining via Fc receptors," and then incubated with FITC-conjugated anti-CD4, PE-conjugated anti-CD8, FITCconjugated anti-IgG/lgM (H + L), or PE-conjugated anti-B220 MoAbs for 30 minutes at 4°C. The cells were then washed twice with PBS before fixing in 1% paraformaldehyde. Two-color flow cytometric analysis of IO4 labeled cells was performed using a FACScan (Becton Dickinson, Mountain View, CA). The FACScan was calibrated using PE-and FITC-conjugated nonspecific IgG antibodies. The splenic cell population containing mainly lymphocytes (including GVHD blasts) was gated by forward-and side-scatter paraneters.
TNF-a ussuy. Levels of TNF-a in tissue culture supernatants were determined by sandwich ELISA using specific antimurinc MoAbs for capture and detection (Pharmingen).
An alkaline phosphatase kit (Vector Laboratories, Burlingame, CA) was used for detection, and a standard curve was generated to detertnine cytokine concentration in the sample. The detection limit of this assay was approximately 20 pg/mL.
Determination of NO production. An assay to detect NO in biologic samples has been described previously.'3 Because NO quickly degrades into stable metabolites, we followed standard procedures and measured NO production by assessment of nitrite (NO;) levels. In brief, SO pL tissue culture supernatants was added to SO p L freshly prepared Griess reagent (a I : I solution of 0.1% N-1 I -naphthyl]ethylenediamine and I % sulfanilamide/S% H,PO,) i n 96-well microtiter plates and incubated for 5 minutes at roonl ternperature. For detection of circulating NO:, serum was deproteinixd with sulfosalicylic acid and then buffered with NH4CI/NaOH. A few granules of Zinc (Sigma) were added, and the mixture was incubated for 10 minutes before adding an equal volume of Griess reagent. This reagent reacts with NO; to form a purple azo dye. and the optical density of this compound was measured at S S 0 nm using a Microplate Reader (Bio-Rad Laboratories, Hercules, CA). The quantity of NO: was calculated using a dilution curve of a standard solution of NaN02. The curve was linear in the range from 0 to 200 pmol/L. and the detection limit of this assay was 1 . 0 pmol/L NO:.
Sfutisticul unulysis. Values are the mean 2 SEM. For btatistical analysis, the nonparametric Mann-Whitney U test was used.
RESULTS
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to LPS is associated with enhanced NO and TNF-a production. We first analyzed GVHID in a BMT model across minor HA barriers (B10.BR + CBA) in terms of cell-surface phenotypes and LPS-induced TNF-a and NO production. Acute GVHD in irradiated CBA hosts was induced by transplantation of a mixture of bone marrow ( 5 X 10' ) and freshly isolated nylon-wool-purified T cells ( I X IO6) from BlO.BR donor mice. Transplanted B10.BR mice served as syngeneic controls without GVHD. The cell-surface phenotype of splenocytes isolated from recipients on day 13 post-BMT is shown in Table 1 . CD4+ and CD8' T cells in mice with GVHD expanded approximately threefold to fourfold above levels in syngeneic controls, as previously shown.3'' A paucity of splenic B cells was observed in animals with GVHD because the incidence of mature sIg+ B cells on day 13 was decreased by about threefold ( P < .05) as compared with syngeneic BMT. The incidence of B220-positive (8220') (CD45R+) cells was similar to that of B cells expressing slg. However, in syngeneic BMT mice, B220' cells were highly increased, likely reflecting a subset of expanding immature bone marrow cells that contains pre-B cells.'4 We found a profoundly suppressed proliferative response of GVHD splenocytes to the mitogen LPS. LPS-induced proliferation of GVHD splenocytes was more than 35-fold lower than the response of cells from syngeneic BMT control mice, despite the fact that cultures from GVHD mice contained only threefold fewer LPS-responsive sIg' B cells per well. In these and subsequent experiments, proliferative responses of LPSstimulated cells from syngeneic controls at this early time point after BMT were generally small; the SI values varied between approximately 1 .S-fold to threefold above levels obtained with spontaneous proliferation. Moreover, because of the low SI of LPS-stimulated syngeneic splenocyte preparations, it is unlikely that the high numbers of B220+ sIgcells contribute to this modest B-cell response.
LPS-activated splenocytes from mice with GVHD produced large amounts of TNF-a (> IO3 pg/mL; Table l), a proinflammatory cytokine thought to play an important role in the pathophysiology of acute GVHD.22,35 Splenocyte cultures from syngeneic BMT produced levels less than 500 pg/mL; however, this was still significantly higher than the TNF-a production by LPS-stimulated naive splenocytes from B10.BR or CBA mice, where levels were below the detection limit of our assay (ie, <20 pg/mL). Increased TNFa levels by LPS-stimulated splenocytes from mice with GVHD were associated with increased production of NO, as assessed by NO; accumulation in tissue culture supernatants. In contrast, levels of NO produced by activated splenocytes from syngeneic BMT mice were approximately 10-fold lower than after allogeneic BMT (Table 1) . Concentrations of NO in unstimulated cultures were below the detection limit of 1.0 pmol/L NO; (data not shown). We next analyzed whether the development of acute GVHD in our BMT model was associated with increased levels of NO in vivo. Serum was collected from the orbital sinus of mice on days 0, 6, and 13 post-BMT and levels of NO; were determined. Serum NO was significantly increased above levels found in the syngeneic BMT group by day 6, and levels continued to be slightly elevated during progression of GVHD (Fig 1) . It should be noted that NO; levels in syngeneic recipients were not significantly different from those found in naive CBA controls (data not shown). Our data thus indicate that acute GVHD to minor HA is associated with elevated NO production both in vitro and in vivo, as well as increased LPS-induced TNF-a production in vitro.
NO mediates suppression of splenocyte proliferation to LPS. NO has important immunomodulatory properties, since it suppresses lymphocyte function in vitro, including proliferation to mitogen.y~"~36 The impaired proliferation by GVHD splenocytes to LPS could be due to the decrease in B-cell number or to an active suppressive mechanism. To answer the question whether NO mediated suppression of proliferation of GVHD splenocytes to LPS, we investigated whether blockade of NO synthesis would abrogate immunosuppression in our model. BMT was performed as described earlier, and spleen cells were isolated from recipients on day 13 post-BMT. Splenocytes were then cultured in the presence of LPS alone or LPS with NMMA, a specific antagonist for the enzyme NO synthase. erative response of splenocytes from GVHD mice (Fig 2A) to that of splenocytes from TCD-BM control mice (Fig 2B) , suggesting that impaired proliferation is due to an active mechanism of suppression rather than being a reflection of the paucity of B cells in the splenocyte preparations. Simultaneous to increasing the SI, treatment of cultures with NMMA reduced levels of NO produced by GVHD splenocytes to levels secreted by non-GVHD control cultures and to less than IO ymol/L, a threshold concentration of NO; that in preliminary experiments was found to induce suppression of splenocyte proliferation (data not shown).
TNF-a induces N O production in GVHD induced to minor HA. Because NO secretion by mononuclear phagocytes can be induced by TNF-a,"." we next analyzed whether TNF-a was responsible for enhanced NO production during GVHD to minor HA. Our data show that neutralization of TNF-a with anti-TNF-a antibody completely abrogated synthesis of NO by LPS-stimulated GVHD splenocytes (Fig  3) . At a 1:40 (vol/vol) concentration of antibody, levels of NO were not different from levels produced by cells from Dilution anti TNF-a mAb impaired splenocyte proliferation in our BMT model. GVHD was induced and recipient splenocytes were restimulated with LPS as described earlier. A specific polyclonal antibody neutralizing the bioactivity of murine TNF-a was present in some cultures. In the absence of anti-TNF-a, proliferation of GVHD splenocytes was suppressed, as expected (Fig 4A) . 
LfS. We next investigated whether TNF-a contributed to
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For personal use only. on September 24, 2017. by guest www.bloodjournal.org From in a second, nonirradiated P * F, BMT model and determined whether hyporesponsiveness to LPS was mediated by the same pathway. Normal B6AFl mice were injected with freshly isolated splenocytes from B6 or syngeneic B6AF, donor mice, and splenocytes from recipients were isolated and stimulated with LPS on day 7 post-BMT. NO production in splenocyte cultures from recipients of allogeneic BMT was significantly increased above levels in syngeneic cultures ( P < .05). At the same time, the proliferative response to LPS was suppressed by approximately 3.5-fold. Neutralization of TNF-a significantly inhibited NO production and increased proliferation fivefold. These data demonstrate that induction of NO by TNF-a is an important pathway leading to suppression of proliferative responses whether GVHD is induced to minor HA or to MHC antigens ( Table 2) .
DISCUSSION
In this study, we have shown that TNF-a and NO form two pathways that are causally linked in a mechanism that inhibits proliferation of B lymphocytes during acute GVHD. Our experimental data show that systemic NO levels are elevated during GVHD (Fig I ) and that NO mediates the failure of B cells from GVHD mice to respond to LPS in vitro (Fig 2) . We further demonstrated that the production of NO is dependent on excess TNF-a production (Table 1 and Fig 3) .
Our hypothesis that the TNF-a and NO pathways are causally linked in a mechanism that leads to GVHID predicts that (1) blockade of TNF-a production during acute GVHD should prevent both NO secretion and B-cell unresponsiveness; ( 2 ) suppression of lymphocyte function by TNFa should occur only with excess NO production; and (3) inhibition of NO production with NMMA should restore lymphocyte function but not affect TNF-a production. Indeed, the neutralization of TNF-a secretion in cultures containing splenocytes isolated from GVHD mice on day 13 posttransplant restored LPS-induced proliferation to levels found in syngeneic BMT controls (Fig 4) . Furthermore, addition of NMMA to splenocyte cultures restored LPS-induced proliferation to levels found in non-GVHD controls (Fig 2) , even though it did not substantially affect TNF-a production by GVHD splenocytes (Fig 5) . NMMA did not independently restore proliferation, because its addition to control cultures without LPS had no effect (data not shown). Lastly, proliferative responses to LPS in control cultures containing splenocytes from naive mice or from syngeneic BMT mice were not decreased by addition of exogenous TNF-a, or increased by addition of anti-TNF-a MoAb (data not shown). This lack of effect shows that TNF-a per se does not prevent proliferation to mitogen. Moreover, addition of exogenous recombinant murine TNF-a to cell cultures did not increase NO production by splenocytes from syngeneic mice to detectable levels.
The observation that TNF-a elicits high levels of NO in splenocytes isolated from GVHD mice but not in cells from syngeneic mice is of interest. This difference may be due to the fact that TNF-a cannot by itself induce NO production Addition of anti-TNF-a at dilutions of 1:40 or 1:400, respectively, completely restored proliferation to levels observed in syngeneic controls. In cultures of splenocytes from mice following syngeneic BMT, addition of anti-TNF-a did not influence the proliferative response of B cells to LPS ( Fig  4B) . The presence of TNF-a per se did not cause increased suppression, because addition of recombinant murine TNFa ( 1 0 % pg/mL) to splenocyte cultures from syngeneic BMT recipients did not affect their proliferation to LPS (data not shown). Taken together, these data indicate that the impaired B-cell proliferation in this GVHD model to LPS is associated with enhanced TNF-a production, but that TNF-a alone is not able to mediate this GVHID. Our data suggest that TNFa induces NO secretion and NO promotes the suppressed response of GVHD splenocytes to LPS. However, it was still possible that the NO synthase inhibitor NMMA might have restored proliferation nonspecifically: for example, by suppression of cytokine secretion. To further evaluate whether immunosuppression in our GVHD model is indeed mediated by the TNF-a/NO pathway, we cultured splenocytes in the presence of LPS and NMMA as described earlier.
Levels of TNF-a were subsequently measured in tissue culture supernatants. Figure 5 shows that TNF-a levels were completely unaffected by treatment with NMMA. In addition, the presence of NMMA did not affect spontaneous proliferation in any of the groups examined (data not shown), ruling out the possibility that NMMA acted as an independent mitogen. Taken together, these data show that NO appears to act at a point distal to TNF-a production in the suppression of LPS-stimulated proliferation during GVHD.
Restoration of immune responses a f e r inhibition of TNFa-dependent NO secretion in P + F, BMT. These data establish causal relationships between TNF-a, NO, and suppression of splenocyte function in a model of GVHD to minor HA. In a final set of experiments, we analyzed GVHID activation phase in mice developing acute GVHD, but not in recipients of syngeneic T cells or T-cell-depleted allogeneic bone m a r r o~, 2 "~~"~" and it has been shown to prime macrophage function during GVHD." Recent experiments performed in our laboratory suggest that the presence of both IFN-y and TNF-a may be necessary to induce mononuclear phagocytes to produce excess NO during acute GVHD.4"" In this study, splenocyte preparations of the two BMT groups were not normalized for slg' cells. GVHD splenocyte cultures contained approximately threefold fewer mature LPS-responsive B cells than syngeneic BMT cultures; however, the proliferative responses of splenocytes were decreased by almost 40-fold (Table l) . These data are consistent with an earlier report that demonstrated a transient elimination of mature B cells in GVHD spleens. B-cell function was impaired even before this depletion and responses remained subnormal long after lymphocyte numbers had recovered, ' showing that suppressed B-cell responses to LPS cannot be solely ascribed to the paucity of B cells in splenocyte preparations from mice with GVHD.
Previous studies have shown that excessive secretion of TNF-(w is characteristic of experimental and clinical acute and its inhibition can lead to decreased morbidity and mortality.**." Despite the causative role of TNF-a in systemic acute GVHD, its potential role in the generation of GVHID has received little attention. NO production is one important mechanism of immunosuppression that has been characterized in a variety of experimental systems and is inducible by TNF-a.
There is recent documentation of increased production of NO after allogeneic BMT.'4"h.4h Our data provide strong evidence that TNF-a and NO are proximal and distal elements, respectively, in the mechanism of B-cell immunosuppression during acute GVHD. The TNF-a/NO pathway impairs proliferative responses to the mitogen LPS whether GVHD is initiated by CD4' or CD8' donor T cells in two separate BMT models. Mononuclear cell-derived NO can suppress lymphocyte function in vitro, including the proliferation to alloantigen or mitogen and the development of CTL responses,"'. ' deficits that are also a hallmark of GVHID.4.4X The potential sources of NO during acute GVHD need to be further investigated. It is highly likely that a principal source of NO is mononuclear phagocytes, similar to a rat model of immunosuppression, where NO secretion ~~~~? l . 2~, 2 4 , ' 5 , 4 1 -4 5 was abolished (and concanavalin A-induced proliferative responses were restored) after selective depletion of macrophages from splenocyte populations."
Our data clearly show that NO mediates impaired B-cell proliferation to LPS; whether it exerts an inhibitory effect on CTL generation during acute GVHD remains to be studied. Moreover, it will be important to investigate the relative importance of the NO pathway with other mechanisms of immunosuppression that are involved in the generation of GVHID. These mechanisms may include generation of nonspecific suppressor
It is likely that, in addition to TNF-a, other cytokines assist to induce the NO pathway that mediates hyporesponsiveness during GVHD. IFN-7 has been implicated independently in the induction of lymphocyte unresponsiveness to mitogenic stimulation during GVHD.5,54"7 Recently, we have shown that the presence of IFN-7 is essential to upregulate NO during acute GVHD in several experimental allogeneic BMT model^.^"" A possible synergy of TNF-a and IFN-y in the induction of the NO pathway and GVHID remains to be investigated.
The full range of pathophysiologic effects of NO after allogeneic BMT is presently unknown. Although the abrogation of NO secretion is able to restore splenocyte proliferation, its production after allogeneic BMT may well be critical to the development of a graft-versus-leukemia effect, to engraftment of hematopoietic stem cells,58 to the prevention of B-cell apoptosis,"~'" or to other aspects of host defense, such as the antimicrobial or tumoricidal activity of macroThus, further investigation is required to determine whether blockade of the NO pathway after allogeneic BMT will offer any potential therapeutic benefits to control morbidity and severity of GVHD.
